Approval · Notice of Compliance 26400 · 2021
FORXIGA: Notice of Compliance 26400
Issued August 10, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26400
- Date
- August 10, 2021
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- Expanded indication and updated the product monograph to the 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FORXIGA | Not yet assigned | — |
Medicinal ingredients
- DAPAGLIFLOZIN PROPANEDIOL 5 MG per TAB
- DAPAGLIFLOZIN PROPANEDIOL 10 MG per TAB